Tags : Hervycta

Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India

Shots: Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer)  Marketed as 150mg and 440mg multiple dose vials  As per Dr. Reddy, it has four biosimilars commercialized in India Click here to read full press release/ article | Ref: Dr. Reddy Laboratories | Image: Dr […]Read More